Notable Labs Ltd Quick Ratio (NTBL) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Notable Labs Ltd   (NASDAQ: NTBL)

Notable Labs Ltd 's Quick Ratio

NTBL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2024, Quick Ratio fell to 1.39 below Notable Labs Ltd average.

Within Major Pharmaceutical Preparations industry 292 other companies have achieved higher Quick Ratio than Notable Labs Ltd in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 492 to 1197.

Explain Quick Ratio?
How much Cash & cash equivalents NTBL´s has?
What are NTBL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NTBL Quick Ratio (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change -44.39 % -69.01 % 12.37 % -64.12 % 17.15 %
Y / Y Cash & cash equivalent Change -83.14 % -69.11 % 136.74 % -24.14 % -28.94 %
Quick Ratio MRQ 1.39 3.4 4.63 7.98 4.58
NTBL's Total Ranking # 1197 # 492 # 487 # 394 # 372
Seq. Current Liabilities Change 22.68 % -5.88 % -1.85 % -50.93 % -31.64 %
Seq. Cash & cash equivalent Change -49.92 % -30.9 % -43.06 % -14.41 % -8.28 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 293
Healthcare Sector # 536
Overall Market # 1197


Quick Ratio Statistics
High Average Low
7.98 4.12 1.08
(Sep 30 2023)   (Dec 31 2019)




Financial Statements
Notable Labs Ltd 's Current Liabilities $ 3 Millions Visit NTBL's Balance sheet
Notable Labs Ltd 's Cash & cash equivalent $ 4 Millions Visit NTBL's Balance sheet
Source of NTBL's Sales Visit NTBL's Sales by Geography


Cumulative Notable Labs Ltd 's Quick Ratio

NTBL's Quick Ratio for the trailling 12 Months

NTBL Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -53.47 % -41.02 % 2.05 % -39.94 % -29.92 %
Y / Y Cash & cash equivalent TTM Growth -46.02 % -30.06 % -24.94 % -51.94 % -54.4 %
Quick Ratio TTM 4.27 5.06 4.58 4.27 3.68
Total Ranking TTM # 3263 # 3023 # 3270 # 273 # 2142
Seq. Current Liabilities TTM Growth -18.3 % -29.39 % 1.57 % -20.59 % 3.56 %
Seq. Cash & cash equivalent TTM Growth -31.02 % -21.95 % 8.93 % -7.96 % -10.63 %

Quick ratio ranking by company, industry and sector >> Back to NTBL Financial Strength Comparisons >> Go to Compare NTBL Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in NTBL's Current Liabilities to $2.95 millions, cumulative Quick Ratio to 4.27 below the NTBL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 440 other companies have achieved higher Quick Ratio than Notable Labs Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 3023 to 3263.

Explain Quick Ratio?
How much Cash & cash equivalents NTBL´s has?
What are NTBL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 441
Healthcare Sector # 913
Within the Market # 3263


trailing twelve months Quick Ratio Statistics
High Average Low
6.15 4.43 1.08
(Sep 30 2019)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Schrodinger Inc   3.78 $ 377.289  Millions$ 99.759  Millions
Aurinia Pharmaceuticals Inc   3.73 $ 331.905  Millions$ 88.995  Millions
Ibio inc   3.71 $ 14.236  Millions$ 3.840  Millions
United Therapeutics Corporation  3.70 $ 2,971.500  Millions$ 803.100  Millions
Theriva Biologics inc   3.70 $ 16.593  Millions$ 4.486  Millions
Pds Biotechnology Corp  3.70 $ 57.734  Millions$ 15.616  Millions
Beyondspring Inc   3.69 $ 14.360  Millions$ 3.891  Millions
Lumos Pharma Inc   3.63 $ 16.799  Millions$ 4.631  Millions
Tvardi Therapeutics Inc   3.59 $ 49.239  Millions$ 13.733  Millions
Cyclerion Therapeutics Inc   3.58 $ 4.588  Millions$ 1.282  Millions
Whitehawk Therapeutics Inc   3.55 $ 78.568  Millions$ 22.147  Millions
Mira Pharmaceuticals Inc   3.54 $ 2.824  Millions$ 0.797  Millions
Corvus Pharmaceuticals Inc   3.54 $ 47.246  Millions$ 13.335  Millions
Arvinas Inc   3.54 $ 1,228.700  Millions$ 347.200  Millions
Synlogic Inc   3.53 $ 19.966  Millions$ 5.652  Millions
Nanoviricides inc   3.53 $ 4.798  Millions$ 1.359  Millions
Telomir Pharmaceuticals Inc   3.53 $ 1.884  Millions$ 0.534  Millions
Immunic Inc   3.51 $ 79.698  Millions$ 22.677  Millions
Geron Corporation  3.51 $ 363.857  Millions$ 103.540  Millions
Chemomab Therapeutics Ltd   3.48 $ 12.727  Millions$ 3.659  Millions
Allakos Inc   3.43 $ 123.121  Millions$ 35.880  Millions
Regeneron Pharmaceuticals Inc   3.36 $ 9,809.000  Millions$ 2,922.600  Millions
Cartesian Therapeutics Inc   3.34 $ 87.227  Millions$ 26.115  Millions
Bridgebio Pharma Inc   3.33 $ 447.771  Millions$ 134.364  Millions
Nuvectis Pharma inc   3.32 $ 18.116  Millions$ 5.460  Millions
Maia Biotechnology Inc   3.30 $ 11.579  Millions$ 3.511  Millions
Can fite Biopharma Ltd   3.26 $ 7.785  Millions$ 2.391  Millions
Syros Pharmaceuticals Inc   3.22 $ 78.964  Millions$ 24.521  Millions
Uniqure N v   3.18 $ 287.877  Millions$ 90.643  Millions
Quoin Pharmaceuticals Ltd   3.17 $ 12.545  Millions$ 3.953  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.